Research map: Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)

Back to the article

Papers in this map

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer · Martin Reck · 2016 · 10309 citations · Cited by this paper
  2. Strategies to target PD-1/PD-L1 in the tumor microenvironment · Yulan Kui · 2026 · 2 citations · Cites this paper
  3. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · 2026 · Related
  4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer · H. Borghaei · 2015 · 9564 citations · Cited by this paper
  5. Unleashing the power of omics-driven liquid biopsy in anti-cancer drug resistance: From biomarker discovery to clinical translation · Bohan Zhang · 2026 · 1 citation · Cites this paper
  6. Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · 2026 · Related
  7. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer · Julie Renee Brahmer · 2015 · 8636 citations · Cited by this paper
  8. Research Progress on Biomarkers for Immunotherapy of Non-Small Cell Lung Cancer · 惠灵 邹 · 2026 · Cites this paper
  9. Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · 2026 · Related
  10. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer · Leena Gandhi · 2018 · 6765 citations · Cited by this paper
  11. Soluble PD-1/PD-L1 biomarkers in NSCLC: prognostic and diagnostic value · Κonstantinos Vachlas · 2026 · Cites this paper
  12. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · 2026 · Related
  13. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC · Mark A. Socinski · 2018 · 3818 citations · Cited by this paper
  14. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · 2026 · Related
  15. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer · Luis G Paz-Ares · 2018 · 3711 citations · Cited by this paper
  16. Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · 2026 · Related
  17. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis · Fabio Scirocchi · 2022 · 46 citations · Cited by this paper
  18. Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · 2026 · Related
  19. Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis · Yan Wang · 2022 · 14 citations · Cited by this paper
  20. Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · 2026 · Related
  21. Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy · Changhong Dong · 2024 · 5 citations · Cited by this paper
  22. Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis · 2026 · Related
  23. Untitled · Cited by this paper
  24. Untitled · Cited by this paper
  25. Untitled · Cited by this paper
  26. Untitled · Cited by this paper
  27. Untitled · Cited by this paper
  28. Untitled · Cited by this paper
  29. Untitled · Cited by this paper
  30. Untitled · Cited by this paper
  31. Untitled · Cited by this paper
  32. Untitled · Cited by this paper
  33. Untitled · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)